Carboplatin and VP-16 for Small Cell Lung Cancer
Author Information
Author(s): W.K. Evans, E. Eisenhauer, P. Hughes, J.A. Maroun, J. Ayoub, F.A. Shepherd, R. Feld
Primary Institution: National Cancer Institute of Canada
Hypothesis
The study investigates the efficacy and safety of carboplatin combined with VP-16 in previously untreated patients with extensive small cell lung cancer.
Conclusion
The combination of VP-16 and carboplatin is active and relatively well tolerated in patients with extensive small cell lung cancer.
Supporting Evidence
- Eighteen patients (56%) achieved an objective response.
- Five (16%) had a complete response and 13 (41%) had a partial response.
- The median survival of all 34 patients was 34.7 weeks.
- Myelosuppression was the main toxicity observed.
- Only 2 of 34 patients had significant renal dysfunction.
Takeaway
Doctors tested a new medicine combination on patients with lung cancer, and it helped many of them feel better without making them too sick.
Methodology
Patients received carboplatin and VP-16 in a specific schedule, and their responses were measured over several treatment cycles.
Potential Biases
Potential biases may arise from the non-randomized nature of the study and the specific patient selection criteria.
Limitations
The study had a small sample size and was not a randomized trial.
Participant Demographics
The median age of participants was 66 years, with a majority being male.
Statistical Information
Confidence Interval
95% confidence limits 38%-73%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website